CALA Calithera Biosciences Inc.

4.1
-0.07  -2%
Previous Close 4.17
Open 4.2
Price To Book 1.15
Market Cap 156315436
Shares 38,125,716
Volume 123,431
Short Ratio
Av. Daily Volume 286,038

SEC filingsSee all SEC filings

  1. 8-K - Current report 19525112
  2. 8-K - Current report 19513369
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167371
  4. 8-K - Current report 181166850
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181053233

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but will not pursue development.
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 top-line data due 2H 2019.
CB-839 + AFINITOR (everolimus)‎ - ENTRATA
Clear cell renal cell carcinoma
Phase 1 oral presentation at ASCO, June 5, 2017.
CX-1158-101
Solid tumors - cancer
Phase 1/2 enrollment commenced August 2016. Oral presentation November 11, 2017 at 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
Phase 2 data due 2020.
CB-839 + Cabozantinib (CANTATA)
Renal cell carcinoma
Phase 2 portion of trial is ongoing.
CB-839 + Panitumumab
Colorectal cancer
Phase 1 poster at ASCO June 4, 2018 8am.
CB-839 + Capecitabine
Solid tumors
Phase 1 presentation at ASCO June 2018. PFS 26 weeks.
CB-839 plus capecitabine
Solid tumors
Phase 1/2 trial to be initiated 1Q 2019.
CB-839 plus talazoparib
Triple negative breast cancer
Phase 1/2 data to be presented 1H 2019.
INCB001158
Solid tumors
Phase 1/2 trial to be initiated 1Q 2019.
Ibrance and talazoparib + CB-839
KRAS mutated NSCLC

SEC Filings

  1. 8-K - Current report 19525112
  2. 8-K - Current report 19513369
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167371
  4. 8-K - Current report 181166850
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181053233
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998740
  7. 8-K - Current report 18998545
  8. 8-K - Current report 18881129
  9. CT ORDER - Confidential treatment order 18823076
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18822821